Afinitor is a new drug that ahs effects on a pathway important in Hodgkin’s disease. A recent study showed soverall response of 47% (95% CI: 24-71%). Four responders remained progression free at 12 months. Several studies of combinations with everolimus for Hodgkin’s are lsited on clinicaltrials.gov. There is also the study: Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine- Based Treatment, NCT01022996.
For Professional version see here